Vedolizumab for adults with moderate-to-severe Crohn’s
Treatments studied
Part of Digestive system clinical trials.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed Crohn’s disease (CD) at least 3 months before screening, proven by a doctor, endoscopy, and biopsy (tissue) when available.
- Your Crohn’s is currently moderately to severely active, based on symptom questionnaires plus a colonoscopy scoring system.
- Your Crohn’s affects at least the ileum (last part of the small intestine) and/or the colon.
- You’ve tried at least one standard Crohn’s medicine—steroids, immune medicines, or a TNF blocker—and it didn’t work well or you couldn’t tolerate it.
- You must not have certain intestinal problems (like an abscess, major bowel resections, a functioning ileostomy/colostomy, or fixed narrowed bowel).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This trial tests whether switching to vedolizumab works better than increasing your adalimumab dose if your Crohn's symptoms or inflammation are coming back despite treatment. It aims to find the best next step for people whose condition is no longer well-controlled.
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.